<i>TARDBP</i> mutations in motoneuron disease with frontotemporal lobar degenerationLina Benajiba, Alexis Brice, Isabelle Le Ber et al.|Annals of Neurology|2009Cited by 302
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemiaKevin Lin, Kris C. Wood, Min Lu et al.|Nature Cancer|2022Cited by 42
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Cancer Discovery|2020Cited by 26
Targeting a lineage-specific PI3Kɣ–Akt signaling module in acute myeloid leukemia using a heterobifunctional degrader moleculeLoïs Kelly, Alexandre Puissant, Justine C. Rutter et al.|Nature Cancer|2024Cited by 25
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Alexandre Puissant, Frank Ling et al.|Blood|2019Cited by 5